curdlan sulfate

Curdlan sulfate is a semisynthetic, sulfated polysaccharide derived from curdlan (a 1→3-β-D-glucan). It is structurally similar to heparin and exhibits a range of pharmacological activities including potent antiviral (notably anti-HIV and anti-dengue), antimalarial, immunomodulatory, and antitumor effects. Curdlan sulfate acts primarily by inhibiting viral entry into host cells—demonstrated for HIV-1 via interference with the HIV envelope glycoprotein gp120 and for dengue virus by binding to the dengue virus envelope protein E at the interface between domains II and III. In malaria, it inhibits *Plasmodium falciparum* rosette formation and cytoadherence *in vitro*, reducing severe complications associated with cerebral malaria. Its anticoagulant activity is significantly weaker than that of heparin. Clinical studies have evaluated its use as adjunct therapy in severe/cerebral malaria without significant adverse effects[1][3][5][6][8]. **Developer:** Ajinomoto

Other names

sulfated 1→3-β-D glucansulfated curdlan